<DOC>
	<DOCNO>NCT02654015</DOCNO>
	<brief_summary>The primary aim minimally invasive surgery ( MIS ) supratentorial intracranial hemorrhage achieve atraumatic evacuation blood product brain prevent secondary injury occur initial bleed . The purpose Phase II randomize trial provide initial assessment efficacy MIES improve outcomes patient supratentorial ICH . Subjects randomize either medical management medical management MIS .</brief_summary>
	<brief_title>INVEST : Minimally Invasive Endoscopic Surgery vs. Medical Management Supratentorial Intraparenchymal Hemorrhage</brief_title>
	<detailed_description>Objective : The primary objective multicenter randomize control trial provide initial assessment safety efficacy minimally invasive endoscopic surgery Apollo evacuation intracerebral hemorrhage ( ICH ) Study Design : This study prospective , randomize , multi-centered international trial enroll 180 patient 30 US center 5 center outside United States . Patients follow 12 month . Patient Population : Patients moderate-large volume ( 20-80 cc ) supratentorial intracerebral hemorrhage ( ICH ) present within 24 hour symptom onset . Patients randomize either minimally invasive endoscopic evacuation Apollo system best medical management ( 2:1 ) . Indication : The Apollo system clear controlled aspiration soft tissue and/or fluid endoscopically guide neurosurgery ventricular system . In present study , investigator propose investigate safety efficacy system minimally invasive evacuation intracerebral hemorrhage .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Intracranial Hemorrhages</mesh_term>
	<criteria>Patient age ≥ 18 ≤ 80 , age &lt; 85 baseline mRS=0 Supratentorial ICH volume ≥ 20 mL &lt; 80 ml ( measure use A x B X C/2 method ) CT/MR demonstrate ICH stability ( &lt; 5 cc growth ) 6 hour admission scan If initial stability scan show growth , second stability scan perform q12h stability demonstrate eligibility study lapse . NIHSS ≥ 6 Presenting GCS 5 15 Historical mRS 0 1 Symptom onset &lt; 24 h prior initial CT Apollo MIES initiate within 72h ictus/bleed SBP control &lt; 160 mmHg sustain level least 6 hour Imaging Expanding hemorrhage stability CT/MR scan `` Spot sign '' identify CTA ( May perform second CTA 12 hour demonstrate resolution ) Hemorrhagic lesion vascular malformation ( cavernous malformation , AVM etc ) , aneurysm , neoplasm Hemorrhagic conversion underlie ischemic stroke Infratentorial hemorrhage Large associate intraventricular hemorrhage require treatment IVHrelated mass effect shift due trap ventricle ( EVD ICP management allow ) Midbrain extension/involvement Coagulation Issues Absolute requirement longterm anticoagulation ( e.g. , Mechanical valve replacement ( bioprostatic valve permit ) , high risk atrial fibrillation ) Known hereditary acquire hemorrhagic diathesis , coagulation factor deficiency Platelet count &lt; 100 x 103 cells/mm3 know platelet dysfunction INR &gt; 1.4 , elevate prothrombin time activate partial thromboplastin time ( aPTT ) , correct otherwise account ( i.e. , lupus anticoagulant ) Patient Factors Presenting GCS 3 4 . High risk condition ischemic stroke ( high risk Afib ( e.g. , mitral stenosis Afib ) , symptomatic carotid stenosis ) Requirement emergent surgical decompression uncontrolled ICP EVD Unable obtain consent patient appropriate surrogate ( patient without competence ) Pregnancy , breastfeeding , positive pregnancy test [ either serum urine ] ( Woman childbearing potential must negative pregnancy test prior study procedure . ) Evidence active infection [ indicate fever ( 100.7 °F ) and/or open drain wound ] time randomization Any comorbid disease condition expect compromise survival ability complete followup assessment 180 day . Based investigator 's judgment , patient necessary mental capacity participate unwilling unable comply protocol follow appointment schedule . Active drug alcohol use dependence , opinion site investigator would interfere adherence study requirement . Currently participate another interventional ( drug , device , etc ) research project .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>intracranial hemorrhage</keyword>
	<keyword>neurosurgery</keyword>
</DOC>